Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797845 | 0.81 | NPC1 (0.54) | ALDH1A1MAPTMEN1NPC1POLB | |
| SCHEMBL6996810 | 0.78 | CA12 (0.42) | ALDH1A1MAPTMEN1KMT2ATSHR | |
| SCHEMBL28553464 | 0.75 | MEN1 (0.45) | ALDH1A1MAPTRXFP1GAAMEN1 | |
| SCHEMBL29962310 | 0.75 | MEN1 (0.45) | ALDH1A1MAPTRXFP1GAAMEN1 | |
| SCHEMBL9589186 | 0.75 | TSHR (0.55) | ALDH1A1MAPTMEN1NPC1POLB | |
| SCHEMBL4504780 | 0.74 | PDE4D (0.50) | MAPTNPC1CYP1A2PDE4DMET | |
| SCHEMBL3939115 | 0.73 | ALDH1A1 (0.59) | ALDH1A1MAPTGAAMEN1POLB | |
| SCHEMBL7127630 | 0.71 | CA12 (0.40) | MET | |
| SCHEMBL6799377 | 0.70 | NPC1 (0.68) | ALDH1A1MAPTMEN1NPC1POLB | |
| SCHEMBL6738366 | 0.70 | TSHR (0.76) | ALDH1A1MAPTGAAMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
| EP-1689717-B1 | SUBSTITUTED ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LTD (GB) | 2007-12-26 | — | — | EP | disclosed |
| EP-1689717-A1 | SUBSTITUTED ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049576-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | HRH4, NR1H2, NR1H3 | ALDH1A1 3492/4885MAPT 3964/4885RXFP1 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.